MARY HELMREICH: Open Payments
NPI 1225604408 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,660 in 109 payments from 15 companies in 2025. Trend: 2023 $1,410 · 2024 $2,049 · 2025 $2,660
Food & beverage: $2,660
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $659 |
| Gilead Sciences, Inc. | 7 | $311 |
| Janssen Biotech, Inc. | 16 | $302 |
| Phathom Pharmaceuticals, Inc. | 6 | $259 |
| Madrigal Pharmaceuticals | 6 | $201 |
| Ipsen Biopharmaceuticals, Inc | 6 | $196 |
| GENZYME CORPORATION | 5 | $173 |
| QOL Medical, LLC | 9 | $169 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $139 |
| Novo Nordisk Inc | 1 | $118 |
Products named: RINVOQ, TREMFYA, VOQUEZNA, REZDIFFRA, DUPIXENT, Sucraid, XIFAXAN, Bylvay.
Industry payments across NV — which companies pay providers there.
